Nexstim
Planning the next phase of growthNexstim
€0.9m prototype research project signedNexstim
Pilot studies lift off in depression and painNexstim
Mapping out the 2020-24 corporate strategyNexstim
€2.3m rights issue is 273% subscribedNexstim
Hitting the right spotNexstim
€2.3m rights issue to progress both NBS and NBTNexstim
Patient registry shows promising outcomes in MDDNexstim
Focussing on strategic prioritiesNexstim
Licensing discussions with academic centre end